Fortrea

Fortrea

Life Sciences Tools & Services
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

$1.9B

Market Cap • 10/2/2026

2023

(3 years)

Founded

2023

(3 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

3,6

P/S

0,7

P/EBITDA

28,2

P/OCF

8,3

P/FCF

9,7

P/E

—

BVPS

5,5

EPS

—

Market Cap

Market Cap

1,9B

EV

2,9B

EV/Revenue

1,1

EV/EBITDA

42,2

EV/EBIT

-264

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-1,4B

Profitability

Gross Margin

19,3%

EBITDA Margin

2,5%

EBIT Margin

—

Net Margin

—

D&A/EBITDA

116%

R&D/Revenue

0%

Capex/Revenue

1,2%

Capex/D&A

40,6%

Capex/OCF

14%

SBC/OCF

26,8%

% PPE

5,8%

% Goodwill

35%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

14,1

Debt/Equity

0%

Current Ratio

1

Quick Ratio

0,9

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium